Invasive pulmonary mucormycosis and aspergillosis in a patient with decompensated hepatic cirrhosis

Jon G. Persichino a,⁎, Argun D. Can b, Tam T. Van c, Michele N. Matthews c, Scott G. Filler a

a Harbor-UCLA Medical Center, Division of Infectious Diseases, 1000 West Carson Street, Torrance, CA 90509, USA
b Harbor-UCLA Medical Center, Division of Respiratory & Critical Care Physiology & Medicine, 1000 West Carson Street, Torrance, CA 90509, USA
c Harbor-UCLA Medical Center, Department of Pathology, 1000 West Carson Street, Torrance, CA 90509, USA

ARTICLE INFO

Keywords:
Invasive Pulmonary Mucormycosis Aspergillosis Hepatic cirrhosis

ABSTRACT

Invasive pulmonary mucormycosis and aspergillosis are rare, life-threatening fungal infections. Most documented cases have been reported in non-cirrhotic patients with diabetes mellitus, neutropenia, or treatment with corticosteroids. The prevalence of each infection is low among patients with hepatic cirrhosis. We report the first likely case of combined invasive pulmonary mucormycosis and aspergillosis in a male with decompensated hepatic cirrhosis. This report also highlights the first non-diabetic case of invasive pulmonary mucormycosis with decompensated hepatic cirrhosis.

1. Introduction

Mucormycosis and Aspergillosis are rare, life-threatening fungal infections with mortality rates reported to be over 50% despite surgical debridement and antifungal therapy [1,2]. *Rhizopus arrhizus*, which is responsible for 70% of all cases of mucormycosis, is associated with a number of clinical diseases (rhino-orbital-cerebral, cutaneous, gastric, and pulmonary mucormycosis) in adults [1]. This fungal infection is particularly recognized worldwide by the healthcare community due to its highly pathogenic nature, which is characterized by rapid tissue destruction and invasion across tissue planes [3]. The major risk factors for mucormycosis include uncontrolled diabetes mellitus with ketoacidosis, hematological malignancy, stem cell and solid organ transplantations, iron chelation therapy with deferoxamine, and corticosteroids. The prevalence of each infection is low among patients with hepatic cirrhosis [2]. The diagnosis of proven, probable, or possible invasive aspergillosis is made by the combination of host status, imaging and mycological findings [5]. The optimal treatment of aspergillosis is administration of voriconazole or isavuconazole, which must be used with caution in patients with hepatic cirrhosis [2,4].

Here, we report a patient with decompensated hepatic cirrhosis who had combined invasive pulmonary mucormycosis and aspergillosis. To our knowledge, this is the first report of invasive pulmonary mucormycosis in a decompensated cirrhotic patient who did not have concomitant diabetes mellitus.

2. Case

A 58-year-old homeless male was found unresponsive in a parking lot and was taken by ambulance to our emergency department (ED). The patient was minimally responsive and able to state only his name; no additional history could be obtained. Initial vital signs in the ED demonstrated a temperature of 37.1 °C, heart rate of 157 beats per minute, respiratory rate of 35 per minute, oxygen saturation of 78% while breathing 15 l of oxygen per minute via face mask, and blood pressure of 80/49 mmHg. On examination, he was ill appearing, icteric, and in respiratory distress. The patient had tachycardia, but no cardiac murmurs. Rales were heard at both lung bases. The entire right lower extremity was erythematous and there was extensive necrosis of the soft tissues extending from the hindfoot to the proximal thigh.

Pertinent laboratory studies on initial presentation revealed a white blood cell count of 19.2 × 10^3 cells/µm³, platelets of 19 × 10^3 cells/µm³, and hepatic cirrhosis [2]. The diagnosis of proven, probable, or possible invasive aspergillosis is made by the combination of host status, imaging and mycological findings [5]. The optimal treatment of aspergillosis is administration of voriconazole or isavuconazole, which must be used with caution in patients with hepatic cirrhosis [2,4].
J.G. Persichino et al.  

Medical Mycology Case Reports 21 (2018) 12–15

The patient was treated with aggressive intravenous (IV) fluid hydration and vasopressors (norepinephrine, vasopressin, and epinephrine) for septic shock. He underwent tracheal intubation for acute hypoxic respiratory failure. The patient received empiric antibiotic treatment with IV vancomycin, piperacillin-tazobactam, and clindamycin. The patient was taken to the operating room where a right disarticulation of his right hip to remove residual necrotic infected tissue. The intraoperative wound cultures grew methicillin-sensitive Staphylococcus aureus and Proteus penneri. On day + 4, 1/4 bottles of the blood cultures grew Aerococcus species and Staphylococcus epidermidis. All four organisms were sensitive to vancomycin and/or piperacillin-tazobactam. No fungal organisms were seen on histopathological analysis of infected tissue and none were isolated from the cultured material.

The patient continued to deteriorate after surgery. On day + 10, given the continued refractory septic shock and bibasilar patchy infiltrates seen on CXR, a bronchoalveolar lavage (BAL) was performed, and thick frothy respiratory secretions with pus were seen. Gram stain and bacterial culture of the BAL specimen were negative, and Xpert MTB/RIF (Cepheid, Sunnyvale, CA) PCR of the sputum was negative for tuberculosis. Cytopathology was not performed.

On day + 12, an infectious diseases consultation was obtained. On initial evaluation, it was noted that the patient had a positive serum 1,3 β-D glucan (> 500, normal < 60). Empiric antifungal treatment with IV micafungin was initiated. Serum galactomannan, cryptococcal antigen, and coccidiomycosis complement fixation tests were negative, as was the urine histoplasma antigen test. On day + 16, a repeat CT scan of the chest revealed worsening of right lung patchy infiltrates (Fig. 1B). A repeat BAL was performed on day + 18, and thick frothy respiratory secretions were again seen. A bronchoscopic biopsy was not performed because of the patient’s coagulopathy and thrombocytopenia.

Nonseptate hyphae were seen on cytologic analysis of the repeat BAL specimen (Fig. 2). The Aspergillus galactomannan assay of the BAL fluid was also positive (6.78, normal < 0.5), and IV voriconazole was initiated on day + 19. A rapidly growing mold grew in cultures of both the BAL sample and a swab from the right chest tube site; the specimens were sent to an outside reference laboratory for identification.

The patient continued to deteriorate. On day + 21, when the total bilirubin increased to 23.5 mg/dL, the micafungin and voriconazole were discontinued and IV L-Amb (5 mg/kg daily) was initiated. On day + 23, a CT scan of the chest showed worsening of the infiltrates in the right lung (Fig. 1C). In addition, a second mold grew in BAL fungal culture. This mold had septate hyphae and conidia, but was not sent for identification. The patient expired on day + 25. Four days later, the rapidly growing mold from the BAL and right chest tube insertion site was identified as R. arrhizus, indicating the presence of invasive pulmonary mucormycosis.

3. Discussion

The data indicate that this patient had both invasive pulmonary mucormycosis and aspergillosis. The diagnosis of mucormycosis was made by the isolation of R. arrhizus from cultures of the BAL fluid and chest tube insertion site, and the finding of broad non-septate hyphae on the BAL cytology specimen. The patient also met the diagnostic criteria for probable invasive pulmonary aspergillosis based on his clinical presentation, the growth from the BAL culture of a second fungus with septate hyphae and conidia that resembled Aspergillus based on colony and microscopic morphologies, and positive BAL galactomannan and serum 1,3 B-D glucan tests [5]. Of note, neither test should be positive in patients with mucormycosis [6]. However, because no formal identification of the second mold from BAL fungal culture was performed, we cannot classify this case as proven aspergillosis [5]. The patient most likely acquired both organisms from the...
natural environment given his homelessness.

This is the first report of a case of combined invasive pulmonary mucormycosis and aspergillosis in a patient with decompensated cirrhosis. The patient did not have any of the traditional risk factors for both infections [2–4]. There was no evidence of diabetes mellitus given the patient’s normal random glucose levels upon initial presentation and during hospitalization. The patient was never neutropenic, had only transient lactic acidosis, and did not receive prolonged corticosteroids.

Liver cirrhosis was the most likely contributing risk factor for both infections in our patient. Invasive aspergillosis is well-described in patients with decompensated liver cirrhosis [2]. Immune dysfunction is a known complication of liver cirrhosis [6]. A decline in both humoral and cell-mediated immunity is a risk factor for bacterial and fungal infections in patients with liver disease, especially in Child-Pugh (CP) class B and C cirrhosis [7–9]. The patient was also at higher risk for pulmonary aspergillosis given his positive emphysematous image findings (Fig. 1A-C) suggestive of chronic obstructive pulmonary disease [2]. Furthermore, the patient was in an iatrogenic iron overload state after receiving 22 units of packed red blood cells for anemia during his early-to-mid hospitalization course. This iron overload state can enhance fungal growth and virulence, possibly contributing to his clinical deterioration [3]. Another potential explanation to consider in our case was the early usage of voriconazole for aspergillosis. Animal models have demonstrated that voriconazole exposure increases virulence of *R. arrhizus* strains and mortality rates in pulmonary disease [2,10,11].

Ultimately, our patient died from his invasive pulmonary mucormycosis and probable aspergillosis complicated by refractory septic shock, multi-organ failure, and severe immune dysfunction from decompensated liver cirrhosis. He also did not receive timely administration of L-Amb, the recommended drug of choice, for invasive pulmonary mucormycosis as this was an unexpected diagnosis given the rarity of this infection in decompensated liver cirrhosis.

To our knowledge, this is also the first case report of invasive pulmonary mucormycosis in a decompensated cirrhotic patient who did not have concomitant diabetes mellitus. The presenting and pertinent demographic and clinical characteristics of prior published case reports of invasive mucormycosis in patients with liver cirrhosis are shown in Table 1. Overall, these cases depict life-threatening infections associated with CP class C cirrhosis (14), diabetes mellitus (12), viral hepatitis C infection (9), rhino-orbital (8) and rhino-orbital-cerebral (7) involvements, CP class B cirrhosis (6), and alcohol use (6). The most intriguing findings are the vast disproportionate number of pulmonary (2) to rhino-orbital/rhino-orbital-cerebral (15) infections, no reports of infected cases associated with CP class A cirrhosis, and all cases with CP class C cirrhosis died despite IV Amb and surgical treatments. Our case differed from the 2 prior published cases (3 & 22) with pulmonary involvement in that there were no other risk factors of diabetes mellitus and chronic steroid usage as well as no association with CP class B cirrhosis.

In conclusion, this case report highlights the need for healthcare professionals to be aware that decompensated liver cirrhosis is considered a risk factor for both invasive pulmonary mucormycosis and aspergillosis.

Acknowledgements
None.

Conflict of interest
There are none.

Ethical form
This study received no funding, and there are no potential conflicts of interests with respect to the research, authorship, and/or publication of this article. We were not able to obtain written and signed consent to publish the case report from the patient, and he had no known family members or legally authorized representatives.

References
[1] A. Ibrahim, B. Spellberg, T. Walsh, D. Kontoyiannis, Pathogenesis of Mucormycosis, Clin. Infect. Dis. 54 (S1) (2012) S16–S22.
[2] M. Falcone, A. Massetti, A. Russo, V. Vullo, M. Venditti, Invasive aspergillosis in
patients with liver disease, Med. Mycol. 49 (2011) 406–413.

[3] A. Ibrahim, D. Kontoyiannis, Update on mucormycosis pathogenesis, Curr. Opin. Infect. Dis. 26 (6) (2013) 508–515.

[4] N. Cicek, N. Yildiz, E. Kadayifci, I. Guke, H. Alpay, Invasive aspergillosis in a patient with end stage renal disease, Med. Mycol. Case Rep. 18 (2017) 12–14.

[5] S. Ascioglu, J. Rex, B. De Pauw, J. Bennett, J. Bille, F. Crokaert, et al., Defining opportunistic invasive fungal infections in immunocompromised patients with cancer and hematopoietic stem cell transplants: an international consensus, Clin. Infect. Dis. 34 (1) (2002) 7–14.

[6] J. Bennett, R. Dolin, Blaser M. Mandell, Douglas, and Bennett’s Principles and Practice of Infectious Diseases, 8th ed., Elsevier, Philadelphia, 2015.

[7] R. Cheruvattath, V. Balan, Infections in patients with end-stage liver disease, J. Clin. Gastroenterol. 41 (2007) 403–411.

[8] C. Fiuza, M. Salcedo, G. Clemente, J. Tellado, In vivo neutrophil dysfunction in cirrhotic patients with advanced liver disease, J. Infect. Dis. 182 (2000) 526–533.

[9] L. Lombarde, A. Capaldi, G. Poccardi, P. Vineis, Peripheral blood CD3 and CD4 T-lymphocyte reduction correlates with severity of liver cirrhosis, Int. J. Clin. Lab. Res. 25 (1995) 153–156.

[10] R. Lewis, G. Liao, W. Wang, R. Prince, D. Kontoyiannis, Voriconazole pre-exposure selects for breakthrough mucormycosis in a mixed model of Aspergillus fumigatus-Rhizopus oryzae pulmonary infection, Virulence 2 (4) (2011) 348–355.

[11] G. Lamaris, R. Ben-Ami, R. Lewis, G. Chamilos, G. Samonis, D. Kontoyiannis, Increased virulence of Zygomycetes in a study involving fly and murine models of zygomycosis, J. Infect. Dis. 199 (9) (2009) 1399–1406.

[12] H. Elsiesy, M. Saad, M. Shorman, S. Amr, F. Abaalkhail, A. Hashim, et al., Invasive mucormycosis in a patient with liver cirrhosis: case report and review of the literature, Hepat. Mon. 13 (8) (2013) e10858.

[13] T. Tokuda, Y. Ono, H. Nishiya, M. Ask, S. Yamanouchi, O. Kunii, et al., An autopsy case of fungal (Mucor) cerebral aneurysm, Kanenshokagaku Zasshi 69 (4) (1995) 439–443.

[14] H. Tojima, T. Tokudome, T. Otsuka, Chronic pulmonary mucormycosis that developed in preexisting cavities caused by tuberculosis in a patient with diabetes mellitus and liver cirrhosis, Nihon Kyobu Shikkan Gakkai Zasshi 35 (1) (1997) 100–105.

[15] S.H. Lee, Y.G. Son, S.S. Sohn, S.W. Ryu, Successful treatment of invasive gastric mucormycosis in a patient with alcoholic liver cirrhosis: a case report, Exp. Ther. Med. 8 (2014) 401–404.

[16] K. Corey, N. Gupta, S. Agarwal, H. Xiao, Case 32-2013: a 55-year-old woman with autoimmune hepatitis, cirrhosis, anorexia, and abdominal pain, New Engl. J. Med. 369 (16) (2013) 1545–1553.

[17] A. Ayadi-Kaddour, E. Brahim, A. Marghli, O. Ismail, L. Helal, M. Milika, et al., Fatal pulmonary mycosis in a diabetic and cirrhotic patient, Tunis Med. 93 (4) (2015) 259–262.

[18] D. Avelar Rodriguez, G. Ochoa Virgen, R.C. Miranda Ackerman, A tip from the nose: rhinocerebral mucormycosis in a patient with alcoholic liver cirrhosis and cocaine abuse, an uncommon association, BMJ Case Rep. (2017), http://dx.doi.org/10.1136/bcr-2017-220730.